391
VALIDATION OF COPY NUMBER ABERRATION AND METHYLATED DNA MARKERS FOR DIFFERENTIATION OF NON-DYSPLASTIC BARRETT’S ESOPHAGUS FROM BARRETT’S ESOPHAGUS WITH HIGH GRADE DYSPLASIA AND ESOPHAGEAL ADENOCARCINOMA : A MULTICENTER STUDY
Date
May 19, 2024
Tracks
Related Products
PANCREATIC CANCER DETECTION USING METHYLATED DNA MARKERS IN PANCREATIC JUICE: A PROSPECTIVE MULTICENTER VALIDATION STUDY
Colorectal cancer (CRC) remains a leading cause of cancer related mortality worldwide…
INCREASED REFLUX SECONDARY BILE ACIDS ARE ASSOCIATED WITH SHIFTS TO THE MICROBIOME AND TRANSCRIPTOME IN BARRETT’S ESOPHAGUS
Background: Bile acids comprise a major component of refluxate in GERD, the major risk factor for Barrett’s esophagus (BE) and esophageal adenocarcinoma (EAC). Bile acids are metabolized by bacteria, and bacterial composition is also impacted by exposure to bile acids…
CLINICAL OUTCOMES AFTER ENDOSCOPIC MANAGEMENT OF LOW-RISK AND HIGH-RISK T1A ESOPHAGEAL ADENOCARCINOMA : OUTCOMES FROM A LARGE COHORT
Focal cryoballoon ablation (FCBA) is a relatively new ablation modality for the treatment of Barrett’s esophagus (BE) related neoplasia. This prospective, European multicenter study (Euro-Coldplay, NTR NL7253) aimed to evaluate the efficacy and safety of FCBA for the treatment of limited BE…
MOLECULAR DETECTION OF PANCREATIC NEUROENDOCRINE TUMORS USING PLASMA METHYLATED DNA MARKERS
BACKGROUND: Colonic polyposis, which is a risk factor for colorectal cancer (CRC), can be driven by a pathogenic variant in a polyposis gene. However, in many cases germline genetic testing is negative, leaving the cause of the polyposis unknown…